Gsk (GSK) Accounts Payables (2009 - 2026)

Gsk (GSK) has 18 years of Accounts Payables data on file, last reported at -$19.2 billion in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables rose 2.67% year-over-year to -$19.2 billion; the trailing twelve-month figure through Jun 2026 stood at -$19.2 billion (up 2.67% YoY), and the FY2025 full-year result was -$20.5 billion, down 4.37% from the prior year.
• Accounts Payables was -$19.2 billion for Q2 2026 at Gsk, roughly flat from -$19.3 billion in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of -$4.2 billion in Q1 2022 to a low of -$21.2 billion in Q3 2025.
• A 5-year average of -$18.3 billion and a median of -$19.1 billion in 2025 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables surged 79.07% in 2022 and plunged 311.35% in 2023, its largest moves.
• Gsk's Accounts Payables stood at -$19.1 billion in 2022, then retreated by 3.09% to -$19.7 billion in 2023, then dropped by 0.09% to -$19.7 billion in 2024, then dropped by 3.95% to -$20.5 billion in 2025, then increased by 5.95% to -$19.2 billion in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were -$19.2 billion in Q2 2026, -$19.3 billion in Q1 2026, and -$20.5 billion in Q4 2025.